Back to research

Research paper

Fenfluramine for developmental and epileptic encephalopathy with spike-wave activation in sleep (DEE-SWAS): An exploratory study

Early exploratory evidence that fenfluramine (serotonergic agent FDA-approved for Dravet and Lennox-Gastaut) reduces spike-wave index in a majority of treated DEE-SWAS patients. First study testing a mechanistically distinct non-immunomodulatory, non-benzodiazepine option for DEE-SWAS.

Indexed context

Parra-Díaz P, et al.

fenfluraminedee-swasserotonergicexploratorynovel-therapy

Markdown path

content/research/papers/2025-parra-diaz-fenfluramine-dee-swas-exploratory.md

Findings

Early exploratory evidence that fenfluramine (serotonergic agent FDA-approved for Dravet and Lennox-Gastaut) reduces spike-wave index in a majority of treated DEE-SWAS patients. First study testing a mechanistically distinct non-immunomodulatory, non-benzodiazepine option for DEE-SWAS.

Why it may matter for Levi

Adds a mechanistically distinct option to Levi's contingent treatment list, relevant if steroid response is not durable and standard fallbacks are exhausted. Cardiac safety (historical valvular / pulmonary-hypertension associations) requires baseline cardiology workup including a cooperative repeat EKG (still outstanding). Complements the Datta 2026 CBD case report as a non-standard DEE-SWAS option worth tracking.

Paper text

Parra-Díaz et al. (2025) — Fenfluramine for DEE-SWAS exploratory study

Source

Why this paper is in the corpus

Early exploratory evidence that fenfluramine — a serotonergic agent FDA-approved for Dravet and Lennox-Gastaut syndromes — reduces spike-wave index in a majority of treated DEE-SWAS patients. The first study to test a mechanistically distinct non-immunomodulatory, non-benzodiazepine option for DEE-SWAS and a meaningful addition to the emerging-therapy tier.

Key findings

  • Exploratory cohort of DEE-SWAS patients treated with fenfluramine.
  • Majority of treated patients showed reduction in spike-wave index.
  • Provides proof-of-concept that serotonergic modulation can affect sleep-activated epileptiform activity even outside the syndromes where fenfluramine is already approved.
  • Sample size and follow-up duration were limited — findings are exploratory, not definitive.

Levi-relevant takeaways

  • Adds a mechanistically distinct option to Levi's contingent treatment list. Fenfluramine would be relevant if (a) steroid response is not durable, (b) benzodiazepine / sulthiame options are exhausted or not tolerated, and (c) no molecular diagnosis opens a targeted-therapy path.
  • Important cardiac safety considerations apply: fenfluramine has historical associations with valvular heart disease and pulmonary hypertension, which are monitored on an echocardiogram schedule in approved indications. Levi's baseline cardiology workup (including a cooperative repeat EKG — still outstanding) would be prerequisite.
  • Complements the Datta 2026 cannabidiol case report already in the corpus as another non-standard DEE-SWAS option worth tracking.

Citation note

Referenced as [19] in the 2026-04-21 user-supplied comprehensive DEE-SWAS / ESES / CSWS research report.